These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 16393427)

  • 21. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
    Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
    Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
    Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
    Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors.
    Knight C; Danø AM; Kennedy-Martin T
    Adv Ther; 2009 Jan; 26(1):68-88. PubMed ID: 19156372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
    Kim CH; Simmons SC; Wang D; Najafzadeh P; Azad A; Pham HP
    Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D; Deryło Ł; Ryś P; Władysiuk M
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience.
    Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE
    Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.
    Mareque M; Mingot-Castellano ME; López-Fernández MF; Álvarez-Román MT; Oyagüez I
    Eur J Haematol; 2020 Jul; 105(1):94-100. PubMed ID: 32220097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
    Nakamura S; Morimoto A; Oh Y; Hayase T; Kashii Y; Gunji Y; Momoi MY
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):235-7. PubMed ID: 22322137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
    Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
    Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice.
    Holmberg HL; Lauritzen B; Tranholm M; Ezban M
    J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
    Schneiderman J; Nugent DJ; Young G
    Haemophilia; 2004 Jul; 10(4):347-51. PubMed ID: 15230948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study.
    Mingot-Castellano ME; García-Candel F; Benítez-Hidalgo O; Marco A; Méndez Navarro GA; Pérez-Montes R; García Donas G; Canaro M; Paloma MJ; Asenjo B; Calle-Gordo VM; González NP; Rodríguez González R; Caparrón-Miranda IS; Quintana París L; Herrero S; Nuñez R
    Eur J Haematol; 2022 Dec; 109(6):686-695. PubMed ID: 36029160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic decision-making in inhibitor patients.
    Allen G; Aledort L
    Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
    Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
    Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
    Abshire TC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.